Compare IDEXX Laboratories, Inc. (IDXX) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $238.71 (market cap $44.37B). The key difference: IDEXX Laboratories, Inc. and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock are close in size by market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | TTWO | |
|---|---|---|
Market Cap | $44.48B | $44.37B |
Sector | Health | Media |
52-Week High | $766.68 | $262.29 |
52-Week Low | $520.87 | $189.69 |
Enterprise Value | $45.38B | $45.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Take-Two Interactive (TTWO) trades at $239.04, up 1.0% on the day, with a bullish technical outlook as the price approaches resistance near $240. The company reported three consecutive quarterly EPS beats but posted a net loss of -$4.48B in FY2025, with revenue growth to $5.63B. Investor focus remains on the upcoming Grand Theft Auto VI release, driving positive sentiment despite recent profitability challenges.
The stock offers significant upside to the consensus price target of $302.50, supported by strong analyst buy ratings (78.95%), but carries risks from high debt levels and negative margins. Near-term catalysts include Q2 2026 earnings on August 7, 2026, though execution on GTA VI and cost management are critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
